Loading
Every dated change on the records linked to Newly diagnosed multiple myeloma, transplant-eligible, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Daratumumab added to VTd increased stringent complete responses and lengthened progression-free survival; approved for transplant-eligible myeloma in 2019 (EU) and 2020 (US).
A milestone in how this cancer is treated.
Early autologous transplant after RVD lengthened progression-free survival compared with RVD alone, with similar overall survival at first analysis.
A milestone in how this cancer is treated.